Cargando…
Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-d-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, b...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691030/ https://www.ncbi.nlm.nih.gov/pubmed/38037130 http://dx.doi.org/10.1186/s13054-023-04761-7 |
_version_ | 1785152652740395008 |
---|---|
author | Novy, Emmanuel Rivière, Jérémie Nguyen, Maxime Arfeuille, Gaëlle Louis, Guillaume Bouhemad, Bélaïd Pottecher, Julien Hecketsweiler, Stéphane Germain, Adeline Laithier, François-Xavier Losser, Marie-Reine Debourgogne, Anne Bernard, Yohann Rousseau, Hélène Baumann, Cédric Luc, Amandine Birckener, Julien Machouart, Marie-Claire Guerci, Philippe |
author_facet | Novy, Emmanuel Rivière, Jérémie Nguyen, Maxime Arfeuille, Gaëlle Louis, Guillaume Bouhemad, Bélaïd Pottecher, Julien Hecketsweiler, Stéphane Germain, Adeline Laithier, François-Xavier Losser, Marie-Reine Debourgogne, Anne Bernard, Yohann Rousseau, Hélène Baumann, Cédric Luc, Amandine Birckener, Julien Machouart, Marie-Claire Guerci, Philippe |
author_sort | Novy, Emmanuel |
collection | PubMed |
description | BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-d-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, but clinical studies have reported inconsistent results, notably because of heterogeneous populations with a low IAC prevalence. This study aimed to identify a high-risk IAC population and evaluate pBDG and sBDG in diagnosing IAC. METHODS: This prospective multicenter noninterventional French study included consecutive critically ill patients undergoing abdominal surgery for abdominal sepsis. The primary objective was to establish the IAC prevalence. The secondary objective was to explore whether sBDG and pBDG could be used to diagnose IAC. Wako(®) beta-glucan test (WT, Fujifilm Wako Chemicals Europe, Neuss, Germany) was used for pBDG measurements. WT and Fungitell(®) beta-d-glucan assay (FA, Associate of Cape Cod, East Falmouth, USA) were used for sBDG measurements. RESULTS: Between 1 January 2020 and 31 December 2022, 199 patients were included. Patients were predominantly male (63%), with a median age of 66 [54–72] years. The IAC prevalence was 44% (87/199). The main IAC type was secondary peritonitis. Septic shock occurred in 63% of cases. After multivariate analysis, a nosocomial origin was associated with more IAC cases (P = 0.0399). The median pBDG level was significantly elevated in IAC (448 [107.5–1578.0] pg/ml) compared to non-IAC patients (133 [16.0–831.0] pg/ml), P = 0.0021. For a pBDG threshold of 45 pg/ml, the negative predictive value in assessing IAC was 82.3%. The median sBDG level with WT (n = 42) at day 1 was higher in IAC (5 [3.0–9.0] pg/ml) than in non-IAC patients (3 [3.0–3.0] pg/ml), P = 0.012. Similarly, median sBDG level with FA (n = 140) at day 1 was higher in IAC (104 [38.0–211.0] pg/ml) than in non-IAC patients (50 [23.0–141.0] pg/ml), P = 0.009. Combining a peritonitis score < 3, sBDG < 3.3 pg/ml (WT) and pBDG < 45 pg/ml (WT) yielded a negative predictive value of 100%. CONCLUSION: In critically ill patients with intra-abdominal infection requiring surgery, the IAC prevalence was 44%. Combining low sBDG and pBDG with a low peritonitis score effectively excluded IAC and could limit unnecessary antifungal agent exposure. Trial registration: The study was registered with ClinicalTrials.gov (ID number 03997929, first registered on June 24, 2019). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04761-7. |
format | Online Article Text |
id | pubmed-10691030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106910302023-12-02 Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study Novy, Emmanuel Rivière, Jérémie Nguyen, Maxime Arfeuille, Gaëlle Louis, Guillaume Bouhemad, Bélaïd Pottecher, Julien Hecketsweiler, Stéphane Germain, Adeline Laithier, François-Xavier Losser, Marie-Reine Debourgogne, Anne Bernard, Yohann Rousseau, Hélène Baumann, Cédric Luc, Amandine Birckener, Julien Machouart, Marie-Claire Guerci, Philippe Crit Care Research BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-d-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, but clinical studies have reported inconsistent results, notably because of heterogeneous populations with a low IAC prevalence. This study aimed to identify a high-risk IAC population and evaluate pBDG and sBDG in diagnosing IAC. METHODS: This prospective multicenter noninterventional French study included consecutive critically ill patients undergoing abdominal surgery for abdominal sepsis. The primary objective was to establish the IAC prevalence. The secondary objective was to explore whether sBDG and pBDG could be used to diagnose IAC. Wako(®) beta-glucan test (WT, Fujifilm Wako Chemicals Europe, Neuss, Germany) was used for pBDG measurements. WT and Fungitell(®) beta-d-glucan assay (FA, Associate of Cape Cod, East Falmouth, USA) were used for sBDG measurements. RESULTS: Between 1 January 2020 and 31 December 2022, 199 patients were included. Patients were predominantly male (63%), with a median age of 66 [54–72] years. The IAC prevalence was 44% (87/199). The main IAC type was secondary peritonitis. Septic shock occurred in 63% of cases. After multivariate analysis, a nosocomial origin was associated with more IAC cases (P = 0.0399). The median pBDG level was significantly elevated in IAC (448 [107.5–1578.0] pg/ml) compared to non-IAC patients (133 [16.0–831.0] pg/ml), P = 0.0021. For a pBDG threshold of 45 pg/ml, the negative predictive value in assessing IAC was 82.3%. The median sBDG level with WT (n = 42) at day 1 was higher in IAC (5 [3.0–9.0] pg/ml) than in non-IAC patients (3 [3.0–3.0] pg/ml), P = 0.012. Similarly, median sBDG level with FA (n = 140) at day 1 was higher in IAC (104 [38.0–211.0] pg/ml) than in non-IAC patients (50 [23.0–141.0] pg/ml), P = 0.009. Combining a peritonitis score < 3, sBDG < 3.3 pg/ml (WT) and pBDG < 45 pg/ml (WT) yielded a negative predictive value of 100%. CONCLUSION: In critically ill patients with intra-abdominal infection requiring surgery, the IAC prevalence was 44%. Combining low sBDG and pBDG with a low peritonitis score effectively excluded IAC and could limit unnecessary antifungal agent exposure. Trial registration: The study was registered with ClinicalTrials.gov (ID number 03997929, first registered on June 24, 2019). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04761-7. BioMed Central 2023-11-30 /pmc/articles/PMC10691030/ /pubmed/38037130 http://dx.doi.org/10.1186/s13054-023-04761-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Novy, Emmanuel Rivière, Jérémie Nguyen, Maxime Arfeuille, Gaëlle Louis, Guillaume Bouhemad, Bélaïd Pottecher, Julien Hecketsweiler, Stéphane Germain, Adeline Laithier, François-Xavier Losser, Marie-Reine Debourgogne, Anne Bernard, Yohann Rousseau, Hélène Baumann, Cédric Luc, Amandine Birckener, Julien Machouart, Marie-Claire Guerci, Philippe Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
title | Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
title_full | Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
title_fullStr | Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
title_full_unstemmed | Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
title_short | Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
title_sort | combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691030/ https://www.ncbi.nlm.nih.gov/pubmed/38037130 http://dx.doi.org/10.1186/s13054-023-04761-7 |
work_keys_str_mv | AT novyemmanuel combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT rivierejeremie combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT nguyenmaxime combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT arfeuillegaelle combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT louisguillaume combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT bouhemadbelaid combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT pottecherjulien combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT hecketsweilerstephane combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT germainadeline combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT laithierfrancoisxavier combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT lossermariereine combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT debourgogneanne combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT bernardyohann combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT rousseauhelene combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT baumanncedric combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT lucamandine combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT birckenerjulien combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT machouartmarieclaire combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy AT guerciphilippe combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy |